Filing Details

Accession Number:
0001127602-20-026662
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-07 16:14:50
Reporting Period:
2020-10-05
Accepted Time:
2020-10-07 16:14:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145197 Insulet Corp PODD Surgical & Medical Instruments & Apparatus (3841) 043523891
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1631895 Shacey Petrovic C/o Insulet Corporation
100 Nagog Park
Acton MA 01720
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-05 15,000 $30.58 33,813 No 4 M Direct
Common Stock Disposition 2020-10-05 15,000 $233.91 18,813 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-10-05 15,000 $0.00 15,000 $30.58
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
52,436 2025-02-09 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 87,495 Indirect By Trust
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
  2. The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $231.090 to $236.170. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  3. This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.